Source: GlobeNewswire Inc.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer’s disease (AD), today presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AßO targeting antibody therapy in early AD, at the Alzheimer’s Association International Conference (AAIC®) 2023, taking place in Amsterdam and online from July 16-20, 2023.
Topline results demonstrated that ACU193 was generally well-tolerated with a compelling overall safety profile, meeting the primary objective of this Phase 1, first-in-human, randomized, double-blind, placebo-controlled study in both single and multiple doses in 60 participants with early AD. Dose levels were 2, 10, 25 and 60 mg/kg for one to three doses administered intravenously. An analysis of change in amyloid plaque load, as measured by positron emission tomography (PET) SUVr, demonstrated a rapid, dose-related mean decrease at the higher dose levels studied (60 mg/kg every 4 weeks [Q4W] and 25 mg/kg every 2 weeks [Q2W]). This finding is comparable to mean amyloid plaque decreases of approved Aß monoclonal antibodies at similar time points in their clinical development. The overall rate of amyloid related imaging abnormalities – edema (ARIA-E) was 10.4%, which included one case of symptomatic ARIA-E (2.1%). Pharmacokinetic results in serum and cerebrospinal fluid (CSF) demonstrated statistically significant dose proportionality and support monthly dosing of ACU193. Statistically significant, dose-related central target engagement was observed as measured by ACU193-AßO complex, establishing the first target engagement assay developed that is specific to an AßO-targeting antibody. An exposure response relationship (Emax) model revealed near maximal target engagement with repeated dosing at 25 mg/kg and 60 mg/kg.
“We are very pleased to present the first clinical data from our Phase 1 INTERCEPT-AD study at AAIC. ACU193’s observed dose-related central target engagement, rapid reduction of amyloid plaque and compelling safety profile validate our confidence in ACU193’s differentiated mechanism of action: selectively targeting amyloid beta oligomers,” said Daniel O’Connell, President and Chief Executive Officer of Acumen. “We believe that the robust data package generated by this comprehensive Phase 1 study establishes ACU193’s broad therapeutic index and guides a future clinical dosing rationale. We look forward to an anticipated interaction with the FDA in the fourth quarter to inform our next phase of development for ACU193.”
ACU193 Demonstrated Rapid, Dose-Related, Statistically Significant Amyloid Plaque Reduction
Higher doses of ACU193 (60 mg/kg Q4W and 25 mg/kg Q2W) showed a statistically significant reduction in amyloid plaque load as determined by amyloid PET after 6-12 weeks (from baseline to endpoint within cohorts (p = 0.01)). This finding provides evidence that ACU193 is active in the brain.
Mean Reduction in Amyloid Plaque (Centiloids)
Recent ABOS News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:47:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:35:38 AM
- Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/13/2024 08:00:00 PM
- Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference • GlobeNewswire Inc. • 05/08/2024 09:47:25 PM
- Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 08:00:00 PM
- Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights • GlobeNewswire Inc. • 03/26/2024 11:00:00 AM
- Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024 • GlobeNewswire Inc. • 03/19/2024 08:00:00 PM
- Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days • GlobeNewswire Inc. • 03/12/2024 08:00:00 PM
- Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting • GlobeNewswire Inc. • 03/08/2024 01:50:00 PM
- Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting • GlobeNewswire Inc. • 02/21/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:32:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 10:02:07 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 10:01:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 12:16:51 PM
- Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer • GlobeNewswire Inc. • 02/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:07:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:06:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:05:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:05:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:04:18 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM